;PMID: 9345343
;source_file_1406.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:42..203] = [t:42..203]
;2)section:[e:207..256] = [t:207..256]
;3)section:[e:260..313] = [t:260..313]
;4)sentence:[e:317..327] = [t:317..327]
;5)sentence:[e:328..487] = [t:328..487]
;6)sentence:[e:488..496] = [t:488..496]
;7)sentence:[e:497..732] = [t:497..732]
;8)sentence:[e:733..884] = [t:733..884]
;9)sentence:[e:885..1005] = [t:885..1005]
;10)sentence:[e:1006..1014] = [t:1006..1014]
;11)sentence:[e:1015..1177] = [t:1015..1177]
;12)sentence:[e:1178..1355] = [t:1178..1355]
;13)sentence:[e:1356..1459] = [t:1356..1459]
;14)sentence:[e:1460..1471] = [t:1460..1471]
;15)sentence:[e:1472..1642] = [t:1472..1642]
;16)section:[e:1646..1690] = [t:1646..1690]

;section 0 Span:0..37
;Am J Clin Oncol  1997 Oct;20(5):527-9
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NN:[5..9] Clin) (IN:[10..15] Oncol)
        (CD:[17..21] 1997) (CD:[22..29] Oct;20-LRB-) (CD:[29..30] 5)
        (-RRB-:[30..31] -RRB-) (CD:[31..35] :527) (::[35..36] -) (CD:[36..37] 9)))

;sentence 1 Span:42..203
;Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in 
;patients with progressive colon cancer after treatment with 5-fluorouracil 
;(5-FU).
;[101..106]:gene-rna:"K-ras"
;[134..158]:malignancy:"progressive colon cancer"
(SENT
  (NP-HLN
    (NP
      (NML
        (NML (NN:[42..52] Irinotecan) (NN:[53..66] hydrochloride))
        (NML (-LRB-:[67..68] -LRB-) (NN:[68..74] CPT-11) (-RRB-:[74..75] -RRB-)))
      (NN:[76..86] resistance))
    (VP (VBN:[87..97] identified)
      (NP (-NONE-:[97..97] *))
      (PP-MNR (IN:[98..100] by)
        (NP (NN:[101..106] K-ras) (NN:[107..115] mutation)))
      (PP-LOC (IN:[116..118] in)
        (NP
          (NP (NNS:[120..128] patients))
          (PP (IN:[129..133] with)
            (NP (JJ:[134..145] progressive) (NN:[146..151] colon)
                (NN:[152..158] cancer)))))
      (PP-TMP (IN:[159..164] after)
        (NP
          (NP (NN:[165..174] treatment))
          (PP (IN:[175..179] with)
            (NP
              (NP (NN:[180..194] 5-fluorouracil))
              (NP (-LRB-:[196..197] -LRB-) (NN:[197..201] 5-FU)
                  (-RRB-:[201..202] -RRB-)))))))
    (.:[202..203] .)))

;section 2 Span:207..256
;Nemunaitis J, Cox J, Meyer W, Courtney A, Mues G.
(SEC
  (FRAG (NNP:[207..217] Nemunaitis) (NNP:[218..220] J,) (NNP:[221..224] Cox)
        (NNP:[225..227] J,) (NNP:[228..233] Meyer) (NNP:[234..235] W)
        (,:[235..236] ,) (NNP:[237..245] Courtney) (NNP:[246..247] A)
        (,:[247..248] ,) (NNP:[249..253] Mues) (NNP:[254..256] G.)))

;section 3 Span:260..313
;Physician Reliance Network, Inc., Dallas, Texas, USA.
(SEC
  (FRAG (DT:[260..269] Physician) (NNP:[270..278] Reliance)
        (NNP:[279..286] Network) (,:[286..287] ,) (NNP:[288..292] Inc.)
        (,:[292..293] ,) (NNP:[294..300] Dallas) (,:[300..301] ,)
        (NNP:[302..307] Texas) (,:[307..308] ,) (NNP:[309..312] USA)
        (.:[312..313] .)))

;sentence 4 Span:317..327
;OBJECTIVE:
(SENT
  (NP (NN:[317..326] OBJECTIVE) (::[326..327] :)))

;sentence 5 Span:328..487
;To determine the prognostic role of a K-ras mutation in tumor tissue  of
;patients with refractory colon cancer who received irinotecan hydrochloride 
;(CPT-11).
;[366..371]:gene-rna:"K-ras"
;[415..438]:malignancy:"refractory colon cancer"
(SENT
  (S
    (NP-SBJ (-NONE-:[328..328] *))
    (VP (TO:[328..330] To)
      (VP (VB:[331..340] determine)
        (NP
          (NP (DT:[341..344] the) (JJ:[345..355] prognostic)
              (NN:[356..360] role))
          (PP (IN:[361..363] of)
            (NP (DT:[364..365] a) (NN:[366..371] K-ras) (NN:[372..380] mutation))))
        (PP-LOC (IN:[381..383] in)
          (NP
            (NP (NN:[384..389] tumor) (NN:[390..396] tissue))
            (PP (IN:[398..400] of)
              (NP
                (NP
                  (NP (NNS:[401..409] patients))
                  (PP (IN:[410..414] with)
                    (NP (JJ:[415..425] refractory) (NN:[426..431] colon)
                        (NN:[432..438] cancer))))
                (SBAR
                  (WHNP-1 (WP:[439..442] who))
                  (S
                    (NP-SBJ-1 (-NONE-:[442..442] *T*))
                    (VP (VBD:[443..451] received)
                      (NP
                        (NP (NN:[452..462] irinotecan)
                            (NN:[463..476] hydrochloride))
                        (NP (-LRB-:[478..479] -LRB-) (NN:[479..485] CPT-11)
                            (-RRB-:[485..486] -RRB-)))))))))))
      (.:[486..487] .))))

;sentence 6 Span:488..496
;METHODS:
(SENT
  (NP (NNS:[488..495] METHODS) (::[495..496] :)))

;sentence 7 Span:497..732
;DNA was extracted from paraffin-stored tumor tissue of 35  patients with
;progressive colon cancer failing treatment with 5-fluorouracil who 
;subsequently received CPT-11 (100 mg/m2 i.v. per week x 4 weeks with 2 weeks
;off  per course).
;[570..594]:malignancy:"progressive colon cancer"
(SENT
  (S
    (NP-SBJ-1 (NN:[497..500] DNA))
    (VP (VBD:[501..504] was)
      (VP (VBN:[505..514] extracted)
        (NP-1 (-NONE-:[514..514] *))
        (PP (IN:[515..519] from)
          (NP
            (NP
              (ADJP (NN:[520..528] paraffin) (HYPH:[528..529] -)
                    (VBN:[529..535] stored))
              (NN:[536..541] tumor) (NN:[542..548] tissue))
            (PP (IN:[549..551] of)
              (NP
                (NP
                  (NP
                    (NP (CD:[552..554] 35) (NNS:[556..564] patients))
                    (PP (IN:[565..569] with)
                      (NP (JJ:[570..581] progressive) (NN:[582..587] colon)
                          (NN:[588..594] cancer))))
                  (VP (VBG:[595..602] failing)
                    (NP
                      (NP (NN:[603..612] treatment))
                      (PP (IN:[613..617] with)
                        (NP (NN:[618..632] 5-fluorouracil))))))
                (SBAR
                  (WHNP-2 (WP:[633..636] who))
                  (S
                    (NP-SBJ-2 (-NONE-:[636..636] *T*))
                    (ADVP (RB:[638..650] subsequently))
                    (VP (VBD:[651..659] received)
                      (NP (NN:[660..666] CPT-11))
                      (PRN (-LRB-:[667..668] -LRB-)
                        (NP
                          (NP (CD:[668..671] 100) (NN:[672..674] mg))
                          (PP (SYM:[674..675] /)
                            (NP
                              (NP (NN:[675..677] m2))
                              (ADVP (RB:[678..682] i.v.))))
                          (PP (IN:[683..686] per)
                            (NP (NN:[687..691] week)))
                          (PP (SYM:[692..693] x)
                            (NP (CD:[694..695] 4) (NNS:[696..701] weeks)))
                          (PP (IN:[702..706] with)
                            (NP
                              (NP
                                (NP (CD:[707..708] 2) (NNS:[709..714] weeks))
                                (ADJP (IN:[715..718] off)))
                              (PP (IN:[720..723] per)
                                (NP (NN:[724..730] course))))))
                        (-RRB-:[730..731] -RRB-)))))))))))
    (.:[731..732] .)))

;sentence 8 Span:733..884
;The first exon of the K-ras gene was amplified by polymerase chain  reaction
;by using K-ras-specific primers followed by mutant enrichment  sequencing.
;[737..747]:variation-location:"first exon"
;[755..760]:gene-rna:"K-ras"
;[783..793]:gene-protein:"polymerase"
;[819..824]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[733..736] The)
         (JJ:[737..742] first) (NN:[743..747] exon))
      (PP (IN:[748..750] of)
        (NP (DT:[751..754] the) (NN:[755..760] K-ras) (NN:[761..765] gene))))
    (VP (VBD:[766..769] was)
      (VP (VBN:[770..779] amplified)
        (NP-1 (-NONE-:[779..779] *))
        (PP (IN:[780..782] by)
          (NP-LGS (NN:[783..793] polymerase) (NN:[794..799] chain)
                  (NN:[801..809] reaction)))
        (PP-MNR (IN:[810..812] by)
          (S-NOM
            (NP-SBJ (-NONE-:[812..812] *))
            (VP (VBG:[813..818] using)
              (NP
                (ADJP (NN:[819..824] K-ras) (HYPH:[824..825] -)
                      (JJ:[825..833] specific))
                (NNS:[834..841] primers))
              (S-ADV
                (NP-SBJ-2 (-NONE-:[841..841] *))
                (VP (VBN:[842..850] followed)
                  (NP-2 (-NONE-:[850..850] *))
                  (PP (IN:[851..853] by)
                    (NP-LGS (NN:[854..860] mutant) (NN:[861..871] enrichment)
                            (NN:[873..883] sequencing))))))))))
    (.:[883..884] .)))

;sentence 9 Span:885..1005
;Survival differences of patients with a K-ras mutation were compared  with
;those of patients with a normal K-ras status.
;[925..930]:gene-rna:"K-ras"
;[992..997]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[885..893] Survival) (NNS:[894..905] differences))
      (PP (IN:[906..908] of)
        (NP
          (NP (NNS:[909..917] patients))
          (PP (IN:[918..922] with)
            (NP (DT:[923..924] a) (NN:[925..930] K-ras) (NN:[931..939] mutation))))))
    (VP (VBD:[940..944] were)
      (VP (VBN:[945..953] compared)
        (NP-1 (-NONE-:[953..953] *))
        (PP-CLR (IN:[955..959] with)
          (NP
            (NP (DT:[960..965] those))
            (PP (IN:[966..968] of)
              (NP
                (NP (NNS:[969..977] patients))
                (PP (IN:[978..982] with)
                  (NP (DT:[983..984] a) (JJ:[985..991] normal)
                      (NN:[992..997] K-ras) (NN:[998..1004] status)))))))))
    (.:[1004..1005] .)))

;sentence 10 Span:1006..1014
;RESULTS:
(SENT
  (NP (NNS:[1006..1013] RESULTS) (::[1013..1014] :)))

;sentence 11 Span:1015..1177
;A total of 21  patients had a normal K-ras sequence and 14 patients had a
;K-ras mutation [GAT,  n = 7; TGT, n = 3; and GCT, AGT, GTT, GAC (codon 13), n
;= 1 each].
;[1052..1057]:gene-rna:"K-ras"
;[1089..1094]:gene-rna:"K-ras"
;[1095..1103]:variation-event:"mutation"
;[1105..1108]:variation-state-generic:"GAT"
;[1118..1121]:variation-state-generic:"TGT"
;[1134..1137]:variation-state-generic:"GCT"
;[1139..1142]:variation-state-generic:"AGT"
;[1144..1147]:variation-state-generic:"GTT"
;[1149..1152]:variation-state-generic:"GAC"
;[1154..1162]:variation-location:"codon 13"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[1015..1016] A) (NN:[1017..1022] total))
        (PP (IN:[1023..1025] of)
          (NP (CD:[1026..1028] 21) (NNS:[1030..1038] patients))))
      (VP (VBD:[1039..1042] had)
        (NP (DT:[1043..1044] a) (JJ:[1045..1051] normal) (NN:[1052..1057] K-ras)
            (NN:[1058..1066] sequence))))
    (CC:[1067..1070] and)
    (S
      (NP-SBJ (CD:[1071..1073] 14) (NNS:[1074..1082] patients))
      (VP (VBD:[1083..1086] had)
        (NP
          (NP (DT:[1087..1088] a) (NN:[1089..1094] K-ras)
              (NN:[1095..1103] mutation))
          (PRN (-LRB-:[1104..1105] -LSB-)
            (FRAG
              (FRAG
                (NP (NN:[1105..1108] GAT))
                (,:[1108..1109] ,)
                (S
                  (NP-SBJ (NN:[1111..1112] n))
                  (VP (SYM:[1113..1114] =)
                    (NP (CD:[1115..1116] 7)))))
              (::[1116..1117] ;)
              (FRAG
                (NP (NN:[1118..1121] TGT))
                (,:[1121..1122] ,)
                (S
                  (NP-SBJ (NN:[1123..1124] n))
                  (VP (SYM:[1125..1126] =)
                    (NP (CD:[1127..1128] 3)))))
              (::[1128..1129] ;) (CC:[1130..1133] and)
              (FRAG
                (NP
                  (NP (NN:[1134..1137] GCT))
                  (,:[1137..1138] ,)
                  (NP (NN:[1139..1142] AGT))
                  (,:[1142..1143] ,)
                  (NP (NN:[1144..1147] GTT))
                  (,:[1147..1148] ,)
                  (NP (NN:[1149..1152] GAC)
                    (PRN (-LRB-:[1153..1154] -LRB-)
                      (NP (NN:[1154..1159] codon) (CD:[1160..1162] 13))
                      (-RRB-:[1162..1163] -RRB-))))
                (,:[1163..1164] ,)
                (S
                  (NP-SBJ (NN:[1165..1166] n))
                  (VP (SYM:[1167..1168] =)
                    (NP
                      (NP (CD:[1169..1170] 1))
                      (ADVP (DT:[1171..1175] each)))))))
            (-RRB-:[1175..1176] -RSB-)))))
    (.:[1176..1177] .)))

;sentence 12 Span:1178..1355
;Median  survival of patients with a normal ras sequence from time of
;treatment with  CPT-11 was 332 days compared with 169 days for patients with
;a K-ras mutation (p  = 0.0036).
;[1221..1224]:gene-rna:"ras"
;[1326..1331]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1178..1184] Median) (NN:[1186..1194] survival))
      (PP (IN:[1195..1197] of)
        (NP
          (NP (NNS:[1198..1206] patients))
          (PP (IN:[1207..1211] with)
            (NP (DT:[1212..1213] a) (JJ:[1214..1220] normal)
                (NN:[1221..1224] ras) (NN:[1225..1233] sequence)))))
      (PP (IN:[1234..1238] from)
        (NP
          (NP (NN:[1239..1243] time))
          (PP (IN:[1244..1246] of)
            (NP
              (NP (NN:[1247..1256] treatment))
              (PP (IN:[1257..1261] with)
                (NP (NN:[1263..1269] CPT-11))))))))
    (VP (VBD:[1270..1273] was)
      (NP-PRD (CD:[1274..1277] 332) (NNS:[1278..1282] days))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[1282..1282] *))
        (VP (VBN:[1283..1291] compared)
          (NP-1 (-NONE-:[1291..1291] *))
          (PP-CLR (IN:[1292..1296] with)
            (NP
              (NP (CD:[1297..1300] 169) (NNS:[1301..1305] days))
              (PP (IN:[1306..1309] for)
                (NP
                  (NP (NNS:[1310..1318] patients))
                  (PP (IN:[1319..1323] with)
                    (NP (DT:[1324..1325] a) (NN:[1326..1331] K-ras)
                        (NN:[1332..1340] mutation)))))))
          (PRN (-LRB-:[1341..1342] -LRB-)
            (S
              (NP-SBJ (NN:[1342..1343] p))
              (VP (SYM:[1345..1346] =)
                (NP (CD:[1347..1353] 0.0036))))
            (-RRB-:[1353..1354] -RRB-)))))
    (.:[1354..1355] .)))

;sentence 13 Span:1356..1459
;No differences in age, sex, cancer stage, surgical treatment, or 
;chemotherapy treatment were observed.
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1356..1358] No) (NNS:[1359..1370] differences))
      (PP (IN:[1371..1373] in)
        (NP
          (NP (NN:[1374..1377] age))
          (,:[1377..1378] ,)
          (NP (NN:[1379..1382] sex))
          (,:[1382..1383] ,)
          (NP (NN:[1384..1390] cancer) (NN:[1391..1396] stage))
          (,:[1396..1397] ,)
          (NP (JJ:[1398..1406] surgical) (NN:[1407..1416] treatment))
          (,:[1416..1417] ,) (CC:[1418..1420] or)
          (NP (NN:[1422..1434] chemotherapy) (NN:[1435..1444] treatment)))))
    (VP (VBD:[1445..1449] were)
      (VP (VBN:[1450..1458] observed)
        (NP-1 (-NONE-:[1458..1458] *))))
    (.:[1458..1459] .)))

;sentence 14 Span:1460..1471
;CONCLUSION:
(SENT
  (NP (NN:[1460..1470] CONCLUSION) (::[1470..1471] :)))

;sentence 15 Span:1472..1642
;Determination of the presence  of a K-ras mutation may predict survival in
;patients with progressive colon  cancer after treatment with 5-fluorouracil
;who receive CPT-11.
;[1508..1513]:gene-rna:"K-ras"
;[1561..1586]:malignancy:"progressive colon  cancer"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1472..1485] Determination))
      (PP (IN:[1486..1488] of)
        (NP
          (NP (DT:[1489..1492] the) (NN:[1493..1501] presence))
          (PP (IN:[1503..1505] of)
            (NP (DT:[1506..1507] a) (NN:[1508..1513] K-ras)
                (NN:[1514..1522] mutation))))))
    (VP (MD:[1523..1526] may)
      (VP (VB:[1527..1534] predict)
        (NP (NN:[1535..1543] survival))
        (PP-LOC (IN:[1544..1546] in)
          (NP
            (NP
              (NP (NNS:[1547..1555] patients))
              (PP (IN:[1556..1560] with)
                (NP
                  (NP (JJ:[1561..1572] progressive) (NN:[1573..1578] colon)
                      (NN:[1580..1586] cancer))
                  (PP-TMP (IN:[1587..1592] after)
                    (NP
                      (NP (NN:[1593..1602] treatment))
                      (PP (IN:[1603..1607] with)
                        (NP (NN:[1608..1622] 5-fluorouracil))))))))
            (SBAR
              (WHNP-1 (WP:[1623..1626] who))
              (S
                (NP-SBJ-1 (-NONE-:[1626..1626] *T*))
                (VP (VBP:[1627..1634] receive)
                  (NP (NN:[1635..1641] CPT-11)))))))))
    (.:[1641..1642] .)))

;section 16 Span:1646..1690
;PMID: 9345343 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1646..1650] PMID) (::[1650..1651] :) (CD:[1652..1659] 9345343)
        (IN:[1660..1661] -LSB-) (NNP:[1661..1667] PubMed) (HYPH:[1668..1669] -)
        (JJ:[1670..1677] indexed) (IN:[1678..1681] for)
        (NNP:[1682..1690] MEDLINE-RSB-)))
